Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation

Abstract

Effective treatments for relapsed Ph⁺ALL with T315I mutation are few; CD19 CAR T-cell therapy are a potential therapy for this condition. We reported 7 patients with relapsed Ph⁺ALL with T315I mutation, who were treated pre- or post-allo-HSCT with CD19-specific CAR T-cells. Of the 7 cases, 6 were in CR or CRp within 1 month after the first infusion of CAR T-cells. MRD revealed a rapid decline in 6 patients. BCR/ABL fusion transcripts were negative in 4/5 cases (not performed in 2). Three patients maintained remission without evidence of MRD by QPCR until the final follow-up, of which 2 received anti-CD19 CAR T-cells and ponatinib at the same time. Our study confirmed the efficacy of anti-CD19 CAR T-cell therapy in treatment of relapsed Ph⁺ALL with T315I mutation pre- or post-allo-HSCT and the concurrent applicability of this therapy with ponatinib.

Keywords:

• CD19
• chimeric antigen receptor T-cells
• Philadelphia
• acute lymphoblastic leukemia
• T315I mutation
• Ponatinib

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was jointly supported by the Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Key Medical Center [YXZXA2016002], the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) and National Natural Science Foundation of Jiangsu Province [SBE2018740700].